![if gte IE 9]><![endif]><![if gte IE 9]><![endif]><![if gte IE 9]><![endif]><![if gte IE 9]><![endif]><![if gte IE 9]><![endif]>
Not a Lexis+ subscriber? Try it out for free.
LexisNexis® CLE On-Demand features premium content from partners like American Law Institute Continuing Legal Education and Pozner & Dodd. Choose from a broad listing of topics suited for law firms, corporate legal departments, and government entities. Individual courses and subscriptions available.
LONDON - (AP) GlaxoSmithKline PLC says U.S. patent litigation over the Omega-3 Lovaza drug has been settled, allowing generic drug company Apotex to eventually bring a competitor to market. Glaxo said Wednesday that Norway's Pronova BioPharma, which supplies the heart medicine to Glaxo, has reached a deal that gives Apotex the right. . . . Full version available to lexis.com subscribers.